6M.Needham,F.L.Mastaglia/NeuromuscularDisorders24(2014)4–15
mutationsaremorelikelytodevelopstatinmyopathyandthereforebene tfromcoenzymeQ10supplements[43,44],butthisrequiresfurtherinvestigation.TheroleofmitochondrialdysfunctioninthepathogenesisofstatintoxicityhasbeenextensivelyreviewedbyGolombandEvans[45].
Statinsalsohaveapro-apoptotice ect,aswellasinhibitingcellproliferation,asdemonstratedinvitroinmuscleand broblastcultures,particularlywithcerivastatin[46].Someoftheanti-atherosclerotice ectsofstatinsarebelievedtooccurthroughthisinductionofapoptosis[47]andsupplementationwithisoprenoidshasbeenshowntopreventstatin-inducedapoptosisinvascularsmoothmuscle[48].Statinshavealsobeenlinkedtoup-regulatedexpressionofatrogin-1,akeygeneinvolvedintheinductionofskeletalmuscleatrophy[49].Thereisalsosomeevidencethatchangesincalciumhomeostasismaycontributetostatin-inducedmuscledysfunctionandinjury.Theryanodinereceptors(RyR)inthesarcoplasmicreticulumareinvolvedincalciumreleaseintothecytoplasm,withtheusualpredominantisoforminadultskeletalmusclebeingRyR-1.Inabiopsy-basedstudy,increasedexpressionofRYR-3mRNAwasfoundinpatientswithstructuralmuscledamageindicatingaberrantexpressionofRyRisoformsinstatinmyopathy[50].
Inaddition,itisknownthatstatinsalsohavevariouse ectsontheimmunesystem[51–57].Thesearelikelytoberelevanttothepathogenesisofsomeformsofstatin-associatedmyopathy,suchasthenecrotizingautoimmunemyopathy(NAM)[58,59],whichisassociatedwithautoantibodiestoHMGCoA[56,60],andtotheinductionofothertypesofin ammatory
myopathies[59,61–71]andautoimmunedisorderssuchasmyastheniagravis[72,73].3.Pharmacogenomicstudies
Theideaofusinggeneticpolymorphismstopredicttherapeutice cacyandtoxicityinanindividualisattractive,andtheuseofgeneticvariantstopredictadversedrugreactionshasbeenincreasingoverthepastdecade.Theirimportancehasbeende nedinthecaseofdrugslikeAzathioprine

and6-mercaptopurine,withvariantallelesintheThiopurinemethyltransferase(TPMT)genepredictingpatientsatriskfortoxicityandassistingdoseindividualization[74,75].Warfarinisanotherexample;itnowhasalabelwarningphysicianstoprescribealowerdoseforpatientswithgeneticvariationsintheCYP2C9andVKORC1enzymes[76,77].Thissectionwillreviewthepharmacogenomicsstudiesaccordingtotheirproposedmechanism.
3.1.Genomicvariationsa ectingtherapeutice cacyofstatins
Genomicvariationshavebeenreportedtoaccountforsomeoftheindividualdi erencesinresponsetostatintherapyintermsofe cacyinloweringLDL,triglyceridesorclinicalresponse.TheseincludeapolipoproteinE(APOE)alleles[78–81],HMG-CoAreductasegene(HMGCR)[82],LDLreceptorgene[83],cholesterylestertransferprotein(CETP)gene[84],andtheangiotensin-Iconvertingenzymegene[85],(reviewedin[86]).Forexample,theHMGCRgenewhichencodestheHMG-CoAreductaseenzyme,themaintargetof
热门文档